Dr. Nara is currently Chief Scientific Officer at Keystone Bio Inc. and a former co-founder, President, Chairman and CEO (1997-2017), co-founder of Lantern Pharma and now Chairman Emeritus at Biological Mimetics, Inc. He holds a M.Sc. in Immuno-pharmacology, a combined Doctor of Veterinary Medicine and Ph.D. (retro-virology/oncogenesis) from The Ohio State University, 4 year combined residency in Comparative Pathology and NIH post-doctoral Fellowship at the Armed Forces Institute of Pathology and a NIH respectively. Dr. Nara currently holds the Endowed Eugene Lloyd Chair, Professor in Vaccinology, founding Center Director for the Center for Advanced Host Defense, Immunobiotics, and Translational Comparative Medicine in the Department of Biomedical Sciences, in the College of Veterinary Medicine at Iowa State University and also the Chief Executive Officer, President, Chairman & co-founder of Biological Mimetics, Inc.,. He is also a distinguished Alumni of The Ohio State University College of Veterinary Medicine 2014, and an elected Fellow of the American Association for the Advancement of Science in 2011.

Prof.Giulio Tarro graduated from Medicine School, Naples University (1962). Research Associate, Division of Virology and Cancer Research, Children’s Hospital (1965-1968), Assistant Professor of ResearchPediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. OncologicalVirology Professor, Naples University (1972-1985). ChiefDivisionVirology (1973-2003), Head Department DiagnosticLaboratories, (2003-2006). D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus, 2006 -. Since 2007 Chairman of Committee of Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro HealthResearch Organization lifetime achievement award (2010).President Foundation de Beaumont Bonelli for Cancer Research. His basicresearcheshavebeenconcerned with antigensinducedearlyduring the replicationcycle of human herpes viruses. Another study has involved the identification, isolation and characterization of specific virus-inducedtumourantigens, which were the "fingerprints" left behind in human cancer. Achievements include patents in the field; discovery of RespiratorySyncytial Virus in infant deaths in Naples and of tumorliberatedproteinas a tumour-associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas.

Dr.Cheng is a practising physician with offices in USA and Shanghai, China, integrating conventional medicine with anti-ageing medicine, orthomolecular medicine, and functional medicine. Dr. Cheng is also a public educator and international public speaker with frequent media interviews including China Global TV Network and US media on health and medicine. Dr. Cheng also has numerous publications on health and medicine. Dr. Cheng graduated from Shanghai Medical University and received his medical residency and subspecialty trainings from Shanghai Medical University, the University of Arkansas for Medical Sciences (UAMS), and the National Cancer Institute, National Institutes of Health (Bethesda, MD). Dr. Cheng also received a PhD in biochemistry/Molecular Biology from UAMS.

Dr. Valiante is a vaccine industry thought leader with deep experience in all aspects of vaccine design, development, and clinical testing. A veteran of Chiron, Novartis, GSK, Moderna, and Glyde Bio, he has advanced vaccines and therapeutics to clinics targeting infectious diseases, cancer, allergy, autoimmunity, and ageing. Nick has led clinically successful scientific and technical teams across a multitude of vaccine and biopharma platforms with world-class expertise in mRNA vaccine development. At Chiron/Novartis/GSK Dr. Valiante rose to the level of Global Head of Immunology and Immunotherapy, where he pioneered mRNA technologies as vaccines and therapeutics. In 2015 he joined Moderna Therapeutics during their hyper-growth phase and built their personalized cancer vaccine (PCV) platform (mRNA 4157) and KRAS vaccine program (mRNA 5173). Here, he exploited the unique advantages of mRNA to develop a best-in-class PCV in 2 years, which has recently yielded impressive efficacy data in a Phase IIb trial in melanoma. As Chief Scientific Officer he brings an unparalleled depth and breadth of vaccine and mRNA development experience to the Innovac team. Dr. Valiante holds a BA from Boston University in Evolutionary Biology, a PhD from the University of Pennsylvania in Immunology, and received post-graduate training at Stanford University.

Ajinkya has over 15 years in the pharma industry with leadership in the development of vaccines, cell and gene therapies and the planning and conduct of clinical trials. He has valuable experience in vaccine safety strategy from Sanofi, Janssen, and BioNTech where his product portfolio included vaccines against Influenza, meningitis, COVID-19, Ebola, HIV, Tuberculosis, malaria, HSV, monkeypox and E. coli. His products included vaccines in various stages of development (including FIH as well as marketed products). He has worked on products based on multiple platforms (recombinant protein, adenoviral, inactivated, and mRNA). In addition to many years of experience in safety strategy in clinical development, safety crisis management, Ajinkya has also consulted on small as well as large PV projects to build safety teams and to establish safety databases integrating automated case management and automated report generation where his clients included Sanofi, Novartis, Takeda, and JNJ. Besides infectious diseases, he has previously worked in Oncology, Cell and Gene Therapy. Ajinkya completed his Medical Education (MBBS) from Shivaji University, India, a Master of Science (MS) in Molecular Biology from the University of Alabama (UA), followed by a Master of Business Administration (MBA) at UA. Before coming to the US, Ajinkya managed his own clinic, worked at a hospital as a General Physician and taught at a medical school. Besides Pharmacovigilance and Vaccine Development, Ajinkya is passionate about finding solutions to stress management, preservation of nature, and improving the quality and length of human life.

Brandon Lucke-Wold was born and raised in Colorado Springs, CO. He graduated magna cum laude with a BS in Neuroscience and distinction in honors from Baylor University. He completed his MD/PhD, Master’s in Clinical and Translational Research, and the Global Health Track at West Virginia University School of Medicine. His research focus was on traumatic brain injury, neurosurgical simulation, and stroke. At West Virginia University, he also served as a health coach for the Diabetes Prevention and Management program in Morgantown and Charleston, WV, which significantly improved health outcomes for participants. In addition to his research and public health projects, he is a co-founder of the biotechnology company Swift Science, the pharmaceutical companyProPhos Neuroscience, and wasa science advocate on Capitol Hill through the Washington Fellow’s program.

Brenda F. Seals, PhD, MPH, MA is Professor and Chair, Department of Public Health at The College of New Jersey. With colleagues, she conducted extensive work in vaccine hesitancy among NJ minority groups, vaccine program roll-out among Departments of Health and is beginning a study on vaccine health education best practices for vaccine providers like pharmacists. Her areas of research are COVID-19, cancer, HIV/AIDS, violence and injury and mental health. She has extensive experience working with Native American, Latinx and African American communities. She works with NJ state, county and municipal Departments of Health to identify and remediate COVID-19 health disparities. She was PI for an NIH grant with a subcontract to improve Health Literacy with the Trenton library. She served as an Investigator on many Community-Based Participatory Approach projects including a patient-centred Outcomes Research Institute (PCORI) study of hepatitis among Asian Americans living from Delaware to New York City. And she was an evaluator and oversaw intervention components of a CDC REACH grant geared to improve diets among Chinese, Vietnamese, Korean and Filipino Community Based Organizations serving meals to community members. Another component of the REACH grant works with Asian supermarkets to promote healthier foods and improve store offerings of lower salt, higher fiber and better oil products. With Dr. Greg Seals, she is co-leading studies of the theory of educational energy provided in public health education settings. Most recently she is embarking on a study of a mental health intervention for those experiencing life-changing injuries mostly due to accidents. Dr. Seals teaches Research Methods, Grant Writing and oversees Capstone Projects for the BS and MPH programs.

Prof. Jerzy Leszek is a Professor of Psychiatry, Vice-Head of the Department of Psychiatry, Head of Alzheimer’s Disease Lab at the Medical University in Wroclaw, and Scientific Director of Alzheimer’s Disease Center in Scinawa near Wroclaw, Poland. He graduated at the Medical University of Wroclaw in 2005 and was awarded a doctorate in Wroclaw in 2007 and in 2011- examination for the degree of associate professor of psychiatry and since 2013 he is working as full professor of psychiatry at Wroclaw Medical University. He is the author and co-author of more than 440 papers (especially from old age psychiatry), some chapters to the books published in reputed Polish and international journals and serving as an editorial board member of several journals. He is a Scientific Editor and co-author of the first Polish academic handbook on Alzheimer’s disease and ten another academic handbook from old age psychiatry(Polish and internationals), member of a lot of scientific associations e .g founder and president of the Lower Silesian Association of Alzheimer’s Families, first of its kind in Poland, President of the Scientific Council of Alzheimer’s Disease Center in Okinawa, near Wroclaw, Former President and founder of Polish Psychogeriatric Association, Former Secretary(now a member) of European Old Age Psychiatry and Former Member of Board of Directions of International Psychogeriatric Association.

I completed my DVM and MS degrees in 1982 and 1984 in India and a PhD in virology from the University of Cambridge, U.K. in 1989. Between 1989 and 1995, I worked with internationally known scientists, initially at McMaster University and subsequently at the Vaccine & Infectious Disease Organization and International Vaccine Center in Canada.I joined Purdue University in 1995 and served as the Interim Head of the Department of Comparative Pathobiology twice (2008-10 and 2016-17).I was promoted to Distinguished Professor of Virology in 2018.I also serve as the Infectious Diseases Program Leader for the Purdue Institute of Inflammation, Immunology, and Infectious Disease.I have over 30 years of experience designing human and nonhuman adenoviral vector-based recombinant vaccines. My laboratory is developing the next generation of vaccines for influenza viruses, SARS-CoV-2, and Mycobacterium tuberculosis.

Prof. Yehuda Shoenfeld is the founder and head of the Zabludowicz Center for Autoimmune Diseases, at the Sheba Medical Center, which is affiliated with the Sackler Faculty of Medicine at Tel-Aviv University in Israel. Professor Shoenfeld’s clinical and scientific works focus on autoimmune and rheumatic diseases, and he has published more than 1750 papers in journals such as New Eng J Med, Nature, The Lancet, Proc Nat Acad Scie, J Clin Invest, J Immunol, Blood, FASEB, J Exp Med, Circulation, Cancer and others.

Dr. Malone has years of experience conducting epidemiological research studies, meta-analyses of clinical research, and rural health studies. Her research interests focus on infectious diseases and cardiovascular disease in rural and underserved populations. Her background includes researching social determinants of cardiovascular disease prevalence to add to the body of knowledge generated by the Jackson Heart Study. She is trained in clinical research protocol and behavioural and epidemiological studies.

Zhaohua (Joe) Zhou, Ph.D., is a Research/Review Scientist at the Office of Biotechnology Products, CDER, US Food & Drug Administration. Dr. Zhou's research focuses on the development of laboratory models for the identification and prediction of drug-induced acute allergic reactions. His research methods encompass the current understanding of the mechanisms underlying clinical anaphylaxis, including:
• Drug-specific IgE screening and in vitro Type 1 sensitization model: This involves the detection of drug-binding antibodies and mast cell degranulation to assess the presence of drug-specific IgE.
• Drug-specific IgG/IgM screening followed by complement activation assay: Dr. Zhou investigates the classical and non-classical pathways of complement activation to generate anaphylatoxins (C3a, C4a, and C5a) through the screening of drug-specific IgG/IgM.
• Mast cell degranulation assay: Dr. Zhou directly evaluates mast cell degranulation, which is a key event in allergic reactions.
• Cytokine storm assay: This assay involves the activation of T cells and macrophages using peripheral blood mononuclear cells (PBMC) or whole blood culture to assess the release of cytokines, providing insights into the immune response.
• Contact system (kinin/kallikrein) activation assay: Dr. Zhou investigates the activation of the contact system, specifically the kinin/kallikrein pathway, which plays a role in allergic reactions.
By utilizing these comprehensive models, Dr. Zhou can efficiently determine whether drug quality is a contributing factor to allergic reactions and predict patient sensitivity to specific therapeutics. Additionally, Dr. Zhou possesses regulatory expertise in the FDA, including Biotherapeutic CMC assessment and immunogenicity method assessment.

Dr. Fuerst is a professor in the Department of Cell Biology and Molecular Genetics, at the University of Maryland (UMD). He also served as director of the Institute for Bioscience and Biotechnology Research (IBBR), UMD, in which the Institute’s mission is focused on biomolecular structure-function relationships and measurement sciences with an emphasis on structure-based vaccine design, next-generation protein therapeutics, and macromolecular delivery systems. Dr. Fuerst has over three decades of research and development experience in vaccines and immunotherapeutics. At UMD-IBBR, his current research is focused is on the hepatitis C virus, ebolavirus, and SARS-CoV-2, and the development of innovative delivery systems incorporating small molecule agonists to stimulate potent immunological responses. Prior to joining UMD, he was a founding scientist at MedImmune (now AstraZeneca) and later joined the U.S. Department of Health and Human Services as director of vaccines and biologics in the Office of the Secretary. In this capacity, he helped establish and lead the Biomedical Advanced Research and Development Authority (BARDA) is responsible for the development and acquisition of vaccines and immunotherapeutic products for biodefense and other emerging public health threats.

Dr. Jean Mercier Ythier is a professor of economics at the University of Paris-Panthéon-Assas, France. He graduated from the Institute of Political Studies of Paris (PhD, 1989). He was also a graduate student at Harvard University (1986-87). He went notably through positions of invited research fellow at the University of Montréal (Québec, Canada), assistant professor and associate professor of economics at the University of Paris Panthéon-Sorbonne and professor of economics at the University of Lorraine (France). Prof. Jean Mercier Ythier's research interests include the theory of general competitive equilibrium, microeconomic theory, public economic theory, economic philosophy, altruism, ethics, and topics of economic anthropology.

Prof. Sang HeuiSeogot DVM degree in 1988 from Kyungpook National University, Daegu, South Korea, and completed his PhD in viral immunology in 1997 from Texas A & M University, College Station, Texas, USA. He experienced Postdoctoral studies in the University of Minnesota and St. Jude Children’s Research Hospital, USA from 1998 to 2002. He joined the faculty member in College of Veterinary Medicine, Chungnam National University in 2002. He has published more than 70 papers in reputed journals on viral pathogenesis and vaccine. He founded PioneerVaccineInc.in 2021, which is specialized in developing human viral vaccines based on cells.

Dr. Sun is an Associate Professor with tenure in the Department of Molecular Medicine, College of Medicine at the University of South Florida (USF). He holds courtesy appointments in the Department of Internal Medicine, Cell Biology, Microbiology & Molecular Biology, Department of Chemistry at USF, and USF Genomics. He received his PhD in Natural Sciences from the University of Kiel, Germany, and his Master's Degree in Veterinary Microbiology and Immunology from the Nanjing Agricultural University, China. He received his postdoctoral training in Molecular Microbiology and Biochemistry at Brown University, USA. The research in his laboratory is focused on the pathogenesis of Clostridioides difficult and the development of novel therapeutics including vaccines to prevent/treat C. complicated infection (CDI). He was an NIH (National Institutes of Health) Career Development K01 Awardee. The NIH has continuously supported his laboratory. He has been actively serving NIH study section panels including chairing the NIH study section panel in 2020. He serves as an Associate Editor for “Molecular Medicine”, and Associate topic editor for “Frontiers in Microbiology”, and editorial boards for “Infection and Immunity” and “Applied and Environmental Microbiology”. He received Tufts Institute for Innovation Inaugural Award in 2014. In 2018, he was awarded the "Faculty Outstanding Research Achievement Award" at USF. In 2019, he was awarded the "Excellence in Innovation Award" at USF. He chaired the Research Committee of the College of Medicine at USF from 2019 to 2020. Currently, he serves as the Vice President for the USF Chapter, National Academy of Inventors, USA.

As a bacteriologist, Dr. Biswas has committed to developing crosscutting research programs for targeting mechanisms and control of bacterial infection. He investigates the role of natural products in control of foodborne bacterial colonization in animals & mechanism of antimicrobial activity of these components. Dr. Biswas’s team has also investigated effective natural organic products such as function bioactive extracts from fruit byproducts for an alternative source of therapeutic and sub-therapeutic (growth promoter) antimicrobial components for organic and conventional poultry production. His research focuses on the reduction of the colonization of foodborne bacterial pathogens in the intestine of farm animals, specifically poultry, by using prebiotics, probiotics, and/or their combination (synbiotics)as well as developing vaccines by generating genetically engineered bacteria.

Dr. Zijun Wang is a physician-scientist at Rockefeller University. Her research focuses on understanding immune responses against viral infections, with a particular emphasis on HIV and SARS-CoV-2, as well as developing antibody-based immunotherapies.

Ethan Moss is currently a senior undergraduate student in the 4+1 MPH program at The College of New Jersey with majors in Public Health and Emergency Management and Preparedness. With two years experience at the Princeton and Philadelphia offices of Emergency Management and the Department of Health, he focuses on program planning, implementation, and management. As part of his internship he constructed Point of Distribution Plans for COVID-19 vaccine sites, PHAB accreditation dashboard management, and a landscape review of Princeton Municipalities Emergency Operations plan. His research interests are in COVID-19 Response, and Emergency Management resulting in 3 APHA presentations over the last two years. He is an EMT.

Colin Lester is an Associate Scientist at Vaxart Inc., working on research and development of orally delivered recombinant adenovirus type 5 vectored vaccines. He has expertise in mucosal immunology and in vitro modelling systems. Colin received a Bachelor of Science in Materials Science and Engineering at the University of Washington, with a focus on Nanoscience and Molecular Engineering. During this time, Colin worked in the laboratory of Dr. Miqin Zhang investigating three-dimensional glioblastoma modeling through the use of chitosan-based porous scaffolds. Following graduation from his undergraduate program, Colin began working at Vaxart to evaluate immunogenicity elicited by oral vaccination against norovirus and SARS-CoV-2 in clinical trials. He has contributed to SARS-CoV-2 NHP challenge models, and clinical analytics for both phase I and phase II clinical trials. His subsequent work involved developing an in vitro model with intestinal cell lines to screen transgene presentation efficacy of newly developed rAd5 constructs. Currently, Colin is working on an extension of his previous in vitro modelling work, utilizing patient-derived human intestinal organoids that partially recapitulate the cell types and activity of ileum tissue in a clinical setting.

Dr. Natasha Patterson is currently a Professor of Public Health at The College of New Jersey (TCNJ) in Ewing, NJ, teaching health systems and policy, public health leadership, and health education courses for undergraduate and graduate students. Dr. Patterson has been teaching in higher education for over 16 years. Prior to teaching she worked in the field as a Health Educator, Program Coordinator for a community based organization and a Research Program Manager for a world renowned cancer research center. Her current research interests include social justice and health disparities, decriminalization of drug policy, Black maternal morbidity and mortality policy, and COVID-19 vaccine hesitation and distribution. Dr. Patterson’s most recent journal publication is entitled: An Examination of US COVID-19 Vaccine Distribution in New Jersey, Pennsylvania, and New York.

I was born in Split, Croatia, and graduated from the School of Medicine, University of Zagreb in 1994. I am an MD, Ph.D., specialising in medical microbiology and parasitology with 28 years of experience in clinical microbiology, epidemiology, and public health. I serve as Head of the Dpt for Gastrointestinal Infections at the Public Health Institute of Split and Dalmatia County. My PhD. The thesis was “Epidemiological and Microbiological and Molecular characteristics of Campylobacter jejuni Infections in Split-Dalmatia County: 2007. - 2012.” and I have published many scientific papers. Additionally, I work at the University of Split as an Assistant Professor of Microbiology and as ESCMID-EFWISG Secretary.

Dr. Naushad Khan completed his PhD at the age of 25 years from Jamia Hamdard University and Postdoctoral Studies at the School of Medicine, Department of Microbiology and the Molecular Genetics University of California, Irvine. After that, He joins another Postdoctoral associate at the Department of Immunology and Microbiology, the Scripps Research Institute, California. He has published more than 15 papers in reputed journals and has been serving as an editorial board member and reviewer of repute. He has achieved several prestigious awards and fellowships to date.

Dr. Patrick Mutombo is a Data scientist and the head of the Data Science Unit. He began his career at INRB (Institut National de Recherche Biomédicale) as a Data manager for clinical trials and had no idea that years later he would become the one who transforms data into insight.

Dr Suma Alluri Graduating with a degree in medicine from Yerevan State Medical University, Dr. Suma completed her internship at Osmania Medical College & Hospital. After completing her education, Dr. Suma served a short service commission as a medical officer in AMC (the Indian Army). To complement her degree in medicine, Dr. Suma possesses a Masters in Pathology, a Diploma in Clinical Pathology and a Master’s in Hospital Management. Dr. Suma joined Avalon University 4 years ago. She is a Professor of Pathology in the Department of Diseases, Immunity & Therapeutics (DIT). With her, she brings more than a decade of experience in teaching Pathology to medical students in many prestigious medical colleges recognized by the National Medical Council in India in the capacity of a PG-tutor, Senior Resident & Assistant Professor. Currently, Dr. Suma, along with instructing Avalon’s MD3 & MD4 students in Systemic Pathology through the use of lectures & labs for DIT1 & DIT2 courses, teaches Introduction to Histology for Pre-Med Students as well.

Ghazwan Ahmed Mohammed Raouf is a Laboratory Manager at the Lalav Hospital for Coronaviruses and infectious diseases in Duhok Province.He is a lecturer and Vice Dean at the College of Pharmacy, University of Duhok, Kurdistan region, Iraq. He is a last-year Ph.D. student in Toxicology and has been selected as an international Ph.D. candidate by the Italian University of Tuscia under the framework of the ERASMUS+ Mobility Student Program 2022-2023and funded by the European Commission. He completed his M.Sc. degree in Toxicology from Hamdard University, New Delhi, India 2010-2012, and his B.Sc. degree in Microbiology from the University of Mosul, Iraq 2002-2006. He has participated in two international conferences as a speaker in the United Kingdom (The 24th European Toxicology and Applied Pharmacology Conference, London, UK, 2023) and India (Pharmaceutical ToxicologyConference-New Delhi-India 2010). He has published four papers in reputed international journals and he is a full member of the following associations.

We will be Updated Soon...

Dr. Kalliopi Megariis a Postdoctoral researcher of Aristotle University of Thessaloniki, Greece and an Adjunct lecturer at the University of Western Macedonia in Florina, Greece. She is a psychologist with a history of working in the hospital & healthcare industry. Skilled in Clinical Neuropsychology, Clinical Research, Medical Education, Psychological Assessment and Learning Disabilities. She works both in clinical and in research practice and she provides strong professional healthcare services, graduated from the Aristotle University of Thessaloniki and attended further education at the Department of Educational and Social Policy, University of Macedonia, in people with special needs and disabilities. She holds undergraduate degrees in Nursing and Psychology, as well as a Master’s and a PhD in Neuropsychology from the Aristotle University of Thessaloniki. She has some years of occupational and research experience working with patients who have neurological, psychiatric, and cognitive disorders, as well as chronic disease patients suffering from cancer and cardiovascular diseases. She is the head of the Centre of creative activities for Children and Adults with Disabilities and she also works as a counselling psychologist in Prison, Diavata Thessaloniki, at the School of a second chance. She was the Global Engagement Representative of the SLC International Neuropsychological Society from 2018-2021 and she was a research fellow in the Department of Cardiovascular Surgery at AHEPA Hospital. Currently, she is a Global Membership Committee member of the International Neuropsychological Society and leader of the Rehabilitation of COVID-19 Patients working group of NeuroCOVID International Neuropsychology Taskforce SIG.

Dr. Rosa Lelyana or Rosa Lelyana Soebowo is a Medical Doctor/ PhD of Nutrition/ General Practitioner/Scientist and Editor/ Reviewer of Int Js, Senior Lecturer, and Professional Researcher for the research field related to Coffee/Medicine/Nutrition. She was born in Solo-Indonesia on June 3rd 1972.